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Abstract
Background: Malignant hyperthermia (MH) is an inherited pharmacogenetic disorder of skeletal
muscle, characterised by an elevated calcium release from the skeletal muscle sarcoplasmic
reticulum. The dihydropyridine receptor (DHPR) plays an essential role in excitation-contraction
coupling and calcium homeostasis in skeletal muscle. This study focuses on the gene CACNA1S
which encodes the 1 subunit of the DHPR, in order to establish whether CACNA1S plays a major
role in MH susceptibility in the UK.
Methods: We investigate the CACNA1S locus in detail in 50 independent MH patients, the largest
study to date, to identify novel variants that may predispose to disease and also to characterise the
haplotype structure across CACNA1S.
Results: We present CACNA1S cDNA sequencing data from 50 MH patients in whom RYR1
mutations have been excluded, and subsequent mutation screening analysis. Furthermore we
present haplotype analysis of unphased CACNA1S SNPs to (1) assess CACNA1S haplotype frequency
differences between susceptible MH cases and a European control group and (2) analyse
population-based association via clustering of CACNA1S haplotypes based on disease risk.
Conclusion:  The study identified a single potentially pathogenic change in CACNA1S
(p.Arg174Trp), and highlights that the haplotype structure across CACNA1S is diverse, with a high
degree of variability.
Background
Malignant hyperthermia (MH) is an inherited disorder of
skeletal muscle, which predisposes to an increased release
of calcium into the myoplasm under certain pharmaco-
logical conditions. Inhalational anaesthetics and the mus-
cle relaxant suxamethonium can trigger an MH crisis and
lead to acceleration of muscle metabolism and contractile
activity generating heat and leading to hypoxaemia, met-
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abolic acidosis, rhabdomyolysis and a rapid rise in body
temperature. This condition is potentially fatal if not rec-
ognised and treated promptly.
Biochemical studies have shown that an MH crisis is due
to an abnormal cellular calcium homeostasis within the
skeletal muscle [1]. Within skeletal muscle the sarcoplas-
mic reticulum (SR) controls the process of Ca2+ release,
playing a major role in the process of excitation-contrac-
tion (E-C) coupling. During E-C coupling depolarisation
of the sarcolemma initiates a conformational change in
the voltage-gated Ca2+ channel (dihydropyridine receptor
(DHPR)) subsequently activating the Ca2+ release channel
(Ryanodine receptor (RyR1)) to release Ca2+ from the SR
[2]. During an MH crisis an elevated rate of cellular Ca2+
release from the SR is observed due, in part, to a reduced
activation and increased deactivation threshold of the
RyR1 [3], or from uncoupling of the DHPR-RyR1 interac-
tion [4].
Genetic analyses have demonstrated that MH susceptibil-
ity exhibits locus heterogeneity, with significant observa-
tions for linkage to chromosome 1q [5,6] and 19q [7,8].
The locus on chromosome 19q has been identified as the
gene encoding the skeletal muscle ryanodine receptor
(RYR1) [8], and that on chromosome 1q as the gene
encoding the 1 subunit of the DHPR (CACNA1S) [5].
There is a finely balanced interaction between the gene
products of RYR1 and CACNA1S, which are only begin-
ning to be understood with alterations in both gene prod-
ucts affecting E-C coupling and modifying Ca2+ regulation
[3,4].
Much research into MH susceptibility has been focused on
the RYR1  locus and it is recognised that RYR1 plays a
major role in susceptibility to MH. There are now over
178 mis-sense mutations described across RYR1 that co-
segregate with MH susceptibility, 29 of which have been
functionally characterised and are used diagnostically
(reviewed in [9]). In the UK, RYR1 plays a part in MH sus-
ceptibility in over 70% (394/554) of UK pedigrees. Con-
siderably less, however, is known about CACNA1S.
Previous studies have demonstrated linkage to chromo-
some 1q within MH families that show RYR1 exclusion
[10], but to date there is only a single mis-sense change
(p.Arg1086His) described in CACNA1S  in association
with MH [5]. This change was first detected in a single
extended French family in 12 individuals all diagnosed as
susceptible to MH, and absent from the 6 individuals
diagnosed as normal [5]. In a North American study of 98
independent MH samples this change was also identified
in a single family [11], in 2 from the 5 MH diagnosed indi-
viduals. p.Arg1086His was not detected in 100 independ-
ent normal French chromosomes [5], nor in 150
unrelated North American normal samples [11]. Interest-
ingly, this change has further been described alongside an
RYR1  alteration (p.Pro4973Leu) in a single individual
[12], where the rest of the family diagnosed as MHS were
accounted for by either the RYR1 change (three individu-
als) or the CACNA1S change (two individuals), suggesting
a potentially more complex means of MH susceptibility
involving multiple gene products.
The aim of this study is to investigate the CACNA1S locus
in detail and to determine whether CACNA1S may play a
major role in MH susceptibility in the UK. As targeted
sequencing for RYR1 has led to potential bias in mutation
detection, we have sequenced the full cDNA transcript of
CACNA1S  for novel changes in 50 independent MH
patients. We report here the findings of this sequencing
and subsequent mutation screening. Furthermore, charac-
terisation of the haplotype structure across CACNA1S is
investigated. We present analysis using unphased
CACNA1S SNP data directly to (1) assess CACNA1S hap-
lotype frequency differences between MH susceptible
cases and a population control group and (2) to analyse
population-based association via clustering of CACNA1S
haplotypes based on disease risk.
Methods
In-vitro contracture testing
There is a well defined and standardised protocol for the
laboratory confirmation of suspected MH cases and test-
ing of family members. The in vitro contracture test (IVCT)
involves exposure of skeletal muscle biopsy specimens to
incremental concentrations of halothane or caffeine in an
irrigated tissue bath and the subsequent measurement of
muscle contracture in response to the applied stimulants.
All individuals were phenotyped by the IVCT according to
the European MH Group (EMHG) guidelines http://
www.emhg.org at the MH Investigation Unit at St James's
Hospital, Leeds, UK. The European protocol assigns the
patient to one of three laboratory diagnostic categories,
MHS, MHN or MHE according to whether their muscle
displays increased sensitivity to both, none or only one of
the stimulants respectively. Both MHS and MHE catego-
ries are deemed to represent clinical susceptibility to MH.
Samples
This study utilises the largest worldwide resource of geno-
typed MH samples from patients phenotyped in a single
diagnostic centre. CACNA1S sequencing was performed
on 50 independent UK MH susceptible samples, with
approval by the Leeds East Local Research Ethics Commit-
tee and written informed consent from all patients. These
samples comprise 30 MHS samples and 20 MHE
(responding to halothane but not caffeine) samples; 14 of
these MHE samples are from probands who suffered a
clinical reaction. The remaining 6 MHE samples are the
only available representative from these individual fami-BMC Medical Genetics 2009, 10:104 http://www.biomedcentral.com/1471-2350/10/104
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lies. However, a recent study by our group, using transmis-
sion data, supports the classification of MHE samples as
affecteds [13]. All 50 of these samples have had the RYR1
cDNA transcript sequenced and have had no variants
detected. There are 30 males and 20 females in the cohort
and the ages range from 10-75 years, with a mean of 33
years. The IVCT data for the 50 patients show a median
(range) contracture of 0.6 g (0.2 - 4.7 g) at 2% halothane
and 0.2 g (0 - 3.6 g) at 2 mM caffeine.
Mutation screening was performed on an additional 410
independent UK MH patients to give a total of 460 inde-
pendent MH patients represented. Of the 460 independ-
ent MH patients, 340 (74%) have an RYR1  mis-sense
change assigned; of these, 298 (65%) co-segregate with
disease, 226 (49%) have a functionally characterised
RYR1 change and there are 8 instances of compound het-
erozygosity with two different RYR1  changes (one
instance each of c.1021G>A/c.7025A>G, c.7063C>T/
c.7025A>G, c.7036G>A/c.14817C>A, c.4024A>G/
c.4088C>T, c.5441T>A/c.7528T>C and c.10616G>A/
c.14210G>A and two instances of 7300G>A/7373G>A).
100 independent MHN samples were also screened.
CACNA1S  haplotype analysis was performed on 460
independent UK MH patients, the same as used for muta-
tion screening assays. Population control samples (480)
for the haplotype analysis were obtained from a DNA
panel of Human Random Controls manufactured by the
European Collection of Cell Cultures (ECACC). The DNA
is derived from peripheral blood lymphocytes of UK Cau-
casian donors with informed consent.
CACNA1S sequencing
CACNA1S cDNA sequencing was performed on 50 inde-
pendent MH susceptible individuals, who did not have an
RYR1  mis-sense change after having previously been
sequenced for the RYR1 cDNA transcript. cDNA prepared
from total RNA isolated from muscle biopsy specimens
was used to sequence the ~6.16 kb CACNA1S  cDNA,
using 12 overlapping fragments of approximately 700 bp
in length, read in both the forward and reverse direction
and analysed on an ABI3730.
Mutation analysis
A novel p.Arg174Trp/c.520C>T change in exon 4 causes a
loss of an MspI site, thus further screening analysis was
performed on genomic DNA using the forward primer 5'-
CTC AAG CAT GGA CAG GAC AC-3' and reverse primer
5'-AGG AAG GGA GAG GAG AAA GG-3' to generated an
amplicon of 279 bp. In the normal (c.520*C) this is
cleaved to produce 3 fragments of 49 bp, 67 bp and 163
bp. Cleavage at one of the sites fails to occur in the pres-
ence of the mutated allele, c.520*T, thus generating 2 frag-
ments of 116 bp and 163 bp in length.
The previously described CACNA1S  mutation
p.Arg1086His/c.3257G>A in exon 26 was screened for in
the full cohort of independent UK MH patients using an
assay developed in-house as follows: forward 5' ATG CAC
CCT ACC CTA TCT CC-3' and reverse 5'-GGA GCA GGG
AGC CTA GTT AC-3' primers generate an amplicon of 998
bp in length. In the normal (c.3257*G) this is cleaved by
HhaI to produce 3 fragments of 362 bp, 316 bp and 313
bp. Cleavage at one of the sites fails to occur in the pres-
ence of the mutated allele, c.3257*A, generating 2 frag-
ments of 629 bp and 362 bp in length.
Haplotype analysis
Haplotype construction
Focusing at the genomic DNA level there are >175 SNPs
described across the 73 kb CACNA1S  gene; predomi-
nantly listed in internet databases sources, in particular
the CEPH population of the Hap-Map project http://
www.hapmap.org, and a further 3 identified through in-
house  CACNA1S  sequencing. When concentrating on
SNPs with a minor allele frequency greater than 0.05 the
total number of described SNPs spanning the gene is
reduced to 115, 16 of which are located in exons. Using
the Tagger software on Haploview we selected eight
informative SNPs to span CACNA1S. The final list of SNPs
chosen is detailed in Table 1.
All SNPs were genotyped using Taqman® methodology.
For all SNPs there is an ABI-assay-on-demand available
(Table 1). All allelic discrimination assays were carried out
on an ABI 7900 according to the manufacturer's instruc-
tions. Linkage disequilibrium between the SNPs was cal-
culated using Haploview software [14].
Statistical analysis
The program PHASE (version 2) was used to reconstruct
haplotypes from the unphased CACNA1S genotype data
and to perform case control permutation tests between
MHS samples and population control samples [15,16].
PHASE calculates the posterior probability distribution of
haplotypes through a Bayesian statistical approach, com-
bining a specified prior for a statistical model for popula-
tion genetics and likelihood information. The program
has a function for case control permutation testing. This
tests the null hypothesis that haplotype frequencies are
the same in cases and controls, versus the alternative
hypothesis that haplotype frequencies are different
between the two groups.
The program GENEBPM, a program designed for use with
candidate genes, tests for association of disease with
causal variants at an unseen functional polymorphism
[17,18]. This program makes use of the expectation that a
pair of haplotypes carrying the same disease mutation are
more likely to share a more recent common ancestry thanBMC Medical Genetics 2009, 10:104 http://www.biomedcentral.com/1471-2350/10/104
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a random pair of haplotypes in the population and thus
are more likely to be similar to each other in terms of their
allelic make-up at flanking markers. Furthermore, output
of the algorithm can be used to ascertain clusters of hap-
lotypes that are associated with specific causative variants,
and to estimate the odds of disease for these unobserved
alleles.
Results
CACNA1S sequencing
Full cDNA sequencing identified non-synonymous
changes in CACNA1S in 12 individuals, 24% of the MH
cases. Sequence changes lead to modifications of amino
acids at positions 69 (n = 4), 174 (n = 1), 258 (n = 4), 458
(n = 13), 606 (n = 1), 1541 (n = 4) and 1660 (n = 5) where
the number in parentheses represents the total number of
MH patients with each change. All are present as hetero-
zygous changes, except the change at position 458 which
was also observed in both homozygous forms. However,
the changes at positions 1541 and 1660 are previously
described polymorphisms (rs3850625 and rs13374149
respectively). The change at position 458 has also been
described as polymorphic [5] and indeed was found to be
highly variable in our cohort with a heterozygosity of
0.425. The other substitutions detected were in codons
determining amino acids that are conserved in rabbit, cat,
mouse and zebrafish (NCBI reference sequences
NP_001095190, NP_001033694, NP_001074492.1 and
NP_999891.1 respectively) and are therefore potentially
deleterious mutations rather than infrequent polymor-
phisms. However, the first change p.Ala69Gly, whilst
being detected in 4 MH susceptible individuals, was also
detected in 7 from 100 MHN samples, and is therefore
likely to be a polymorphism. Furthermore, the changes
p.Gly258Asp and p.Ser606Asn, whilst not being detected
in 100 MHN controls, were observed to be frequently dis-
cordant with MH status in families. Within the 4
p.Gly258Asp families there are a total of 24 individuals,
comprising 5 MHS, 7 MHE and 12 MHN samples, and the
p.Gly258Asp change was observed in a total of 3 MHN
samples, 2 MHS and 3 MHE samples, whilst the
p.Ser606Asn was detected in both the MHE and MHN sib-
lings within a single family. There was no example of
compound heterozygosity with these rare changes. These
changes can be added to the growing number of non-syn-
onymous changes reported across CACNA1S, over half
(10) of which are likely to be polymorphisms (see Table
2).
The final mis-sense variation that was detected,
p.Arg174Trp, was found in an MHS sample, was concord-
ant with disease within the family and also not detected in
100 MHN control samples. The mother of the proband
was diagnosed MHS through the IVCT, and also had the
p.Arg174Trp alteration. A sibling of the proband, diag-
nosed normal through the IVCT, did not have the
p.Arg174Trp change. The MH proband, in whom the
p.Arg174Trp was detected, developed intense masseter
muscle spasm and generalised muscle rigidity lasting 8
minutes after administration of the inhalation anaesthet-
ics propofol, fentanyl and halothane and the muscle
relaxant suxamethonium (1.5 mg/kg). Post-operatively
there was severe muscle stiffness that persisted for 2 weeks
and a peak serum creatine kinase concentration of 14,500
IU/L (normal < 220 IU/L). The IVCT results for this indi-
vidual were 0.35 g contracture at 2% halothane and 0.2 g
Table 1: Details of the SNPs selected for inclusion in the CACNA1S haplotype analysis
NCBI reference Locationa Chromosomal positionb Hetc ABI assay number SNP number
rs1546416 Intron42-43 199276179 0.468 C___2826986_1_ 1
rs12029212 Intron32-33 199288242 0.303 C__25474094_10 2
rs7415038 p.Phe801 199305310 0.504 C___3135170_10 3
rs10920105 Intron15-16 199309241 0.468 C__25652884_10 4
rs9427714 p.Gly505 199313734 0.495 C__25652932_10 5
rs2296383 p.Ile199 199327488 0.528 C__15752541_10 6
rs1536129 Intron2-3 199335814 0.439 C___1942693_10 7
rs1325309 Intron1-2 199346081 0.414 C___1942703_20 8
aLocation of each SNP according to reference sequence
bChromosomal position according to NCBI reference sequence for chromosome 1
cHeterozygosity calculated from our data for the 480 population control samplesBMC Medical Genetics 2009, 10:104 http://www.biomedcentral.com/1471-2350/10/104
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contracture at 2 mM caffeine: laboratory classification
(EMHG) MHS.
The cDNA sequencing further identified 3 novel silent
changes in the CACNA1S gene. These were located in 2
different exons; p.Leu766/c.2296C>T minor allele fre-
quency of 0.01 and a heterozygosity of 0.02, and p.Ile781/
c.2343C>T, with a minor allele frequency of 0.031 and a
heterozygosity of 0.06 were located in exon 17 and
p.Pro1622/c.4866C>T with a minor allele frequency of
0.208 and a heterozygosity of 0.33 was located in exon 40.
There is no significant linkage disequilibrium detected
between the markers, with r2 = 0 between 4866*C and
both 2296*C and 2343*C, and r2 = 0.32 between the
neighbouring markers 2296*C and 2343*C. Linkage dis-
equilibrium was also not detected between these markers
and their adjacent markers across CACNA1S, i.e. between
4866*C with either rs3850625*C or rs13374149*G and
nor between 2296*C and 2343*C with rs7415038*T or
rs1684767*C.
Table 2: Reported variants in the coding sequence of CACNA1S
Reported mis-sense changes in CACNA1S
Exo
n
Nucleotide changea Protein change Incidence
b
Population Disease statusc References
1 c.64A>T p.Glu22Val Unknown Unknown unknown ss95806
2 c.205C>G p.Ala69Gly 11 UK polymorphism This study (ss43973054)
4 c.520C>T p.Arg174Trp 1 UK MH This study
6 c.773G>A p.Gly258Asp 4 UK polymorphism This study
10 c.1373T>A p.Leu458His 14 UK & France polymorphism This study, 5
11 c.1582C>G p.Arg528Gly 1 China HOKPP [27]
11 c.1583G>A p.Arg528His 77 Europe, USA, Japan, Korea & 
china
HOKPP [28-43]
12 c.1669G>A p.Arg557His 1 Unknown unknown ss6793785
12 c.1817G>A p.Ser606Asn 1 UK polymorphism This study
21 c.2691G>T p.Arg897Ser 1 France HOKPP [44]
26 c.3257G>A p.Arg1086His 3 USA & France MH [5,11,12]
30 c.3684C>G p.Arg1239Gly 10 USA & Korea HOKPP [28,33,42,45,46]
30 c.3685G>A p.Arg1239His 50 USA, Europe & Japan HOKPP [29,33,34,39,42,45,47]
37 c.4475C>A p.Ala1492Asp 1 Italy polymorphism [48]
38 c.4621C>T p.Arg1541Cys 4 UK polymorphism This study (rs3850625)
40 c.4978G>A p.Arg1660His 5 UK polymorphism This study (rs13374149)
44 c.5404T>C p.Leu1802Ser Unknown UK polymorphism rs12139527
44 c.5525G>C p.Glu1842Asp Unknown UK polymorphism rs1042379
aNumbering based on cDNA ref: ENST00000263942.
bTotal number of independent observations.
cDisease status reported with variant; malignant hyperthermia (MH), and hypokalemic periodic paralysis (HOKPP).BMC Medical Genetics 2009, 10:104 http://www.biomedcentral.com/1471-2350/10/104
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Mutation screening
The p.Arg174Trp change was identified in a single family
showing full concordance with disease status and not
identified in 100 normal controls. Accordingly we
screened for the presence of this site in the full UK cohort
of 410 independent MH families. The p.Arg174Trp
change was not detected in any other UK family.
The previously described CACNA1S  mutation
p.Arg1086His in exon 26 was screened for in the 460
independent UK MH patients. This change was not
detected in any UK MH family, nor the 100 MHN con-
trols.
Haplotype analysis
A total of 460 independent UK MH patients and 480 Cau-
casian population controls were typed for all eight
CACNA1S SNP markers. These 8 SNPs were used to recon-
struct haplotypes from the unphased data using PHASE
and GENEBPM. From GENEBPM there were a total of 23
haplotypes with an estimated population frequency 0.01
(1%), and these are detailed in Table 3, along with a
breakdown of the haplotype frequencies for each study
group (MHS, PC and also the subset of 50 samples that
were sequenced for CACNA1S) calculated using PHASE.
The single SNPs were tested for association with disease
using a Spearman rank correlation between MHS samples
and PC. There was no evidence for significant associations
with any of the markers except p.Ile199, where p = 0.014.
Case control permutation testing was performed between
MHS samples and the population control samples to test
for differences in CACNA1S haplotype frequencies using
the program PHASE. There was a small but significant dif-
ference observed with this comparison (p = 0.02), provid-
ing evidence for association between MH and CACNA1S.
However, for the same comparison using the GENEBPM
program to analysis haplotype relative risk of disease,
there was no categorical evidence of CACNA1S haplotype
association with MH (posterior probability   = 0.46).
To illustrate the posterior similarities between haplotypes
in terms of their risk of carrying causal variants and allelic
make-up, a dendrogram can be constructed. Figure 1
presents a dendrogram of the 23 CACNA1S haplotypes
with estimated relative frequency 1% from the analysis
of MHS cases versus population controls. These 23 haplo-
types are coded according to their relative frequency,
where 1 represents the most frequent haplotype and 23
the least frequent. The dendrogram shows considerable
posterior similarity between haplotypes and demonstrates
no apparent clustering of haplotypes, suggesting that
there is no clear high risk disease variant. Additionally, the
haplotype analysis reveals that there are numerous rela-
tively rare haplotypes (there are only three haplotypes
with a frequency >5% in population controls), suggestive
of an elevated degree of haplotype diversity potentially
resulting from a high rate of recombination across the
locus and a low level of linkage disequilibrium.
To exclude any influence of RYR1 on the analysis, a case
control permutation test in PHASE was also performed
between the 480 population control samples and the 50
samples that have been cDNA sequenced for CACNA1S.
There was no overall significant difference in CACNA1S
haplotype frequency observed between these groups. The
haplotypes H5 and H14 were observed at a noticeably
higher frequency in the 50 sequenced samples (0.099 and
0.058 respectively) than the population controls (0.043
and 0.029 respectively) (see Table 3), however given that
the haplotype frequencies are relatively small these obser-
vations are unlikely to be significant. Further analysis with
GENEBPM also provided no categorical evidence of
CACNA1S  haplotype association with MH (posterior
probability   = 0.415), suggesting that CACNA1S does
not play a major role in MH susceptibility, however due
to the small number in the cDNA sequenced group this
comparison may lack power.
Furthermore, to investigate whether there were any differ-
ences in CACNA1S haplotype frequencies between MH
phenotypes, an additional case control permutation test
was performed on the subset of 50 samples that under-
went cDNA sequencing between the MHS (n = 30) and
MHE (n = 20) samples using all 8 SNPs. There was no sig-
nificant difference in CACNA1S  haplotype frequency
observed between the MHS and MHE samples (p = 0.27);
however, again due to the small numbers in each group
this comparison may lack power.
Discussion
As more is being understood about the nature of suscepti-
bility to MH it is becoming increasingly apparent that it is
complex and cannot always be simply described as auto-
somal dominant. There is evidence for variation in clinical
severity and IVCT phenotype, resulting from the same
mis-sense change in RYR1 [19,20]. There are also reports
of compound heterozygotes in RYR1  [[12,21], unpub-
lished UK observations] and an individual with mutations
in both RYR1 and CACNA1S [12]. Furthermore, we have
previously demonstrated, using transmission disequilib-
rium testing, that multiple interacting gene products affect
susceptibility to MH [10,22]. Even within families that
showed linkage to RYR1 evidence has been provided for
linkage to other loci elsewhere in the genome [10].
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Table 3: Details of the 23 CACNA1S haplotypes with an estimated population frequency  0.01 in at least one group.
Haplotype 
Name
rs1546416 rs12029212 rs7415038 rs10920105 rs9427714 rs2296383 rs1536129 rs1325309 Estimated haplotype frequencies
(Std Error)a
MHS PC 50 sequenced 
samples
H1 2 2 1 1 1 1 1 1 0.084 (0.008) 0.081 (0.007) 0.081 (0.018)
H2 1 2 1 1 1 1 1 1 0.047 (0.007) 0.075 (0.006) 0.055 (0.018)
H3 2 2 2 1 2 2 1 1 0.065 (0.007) 0.059 (0.007) 0.044 (0.014)
H4 2 2 2 2 2 2 2 1 0.05 (0.006) 0.046 (0.006) 0.07 (0.018)
H5 2 1 1 1 1 1 1 1 0.043 (0.008) 0.04 (0.005) 0.099 (0.019)
H6 2 2 2 1 2 2 2 2 0.03 (0.005) 0.05 (0.005) 0.016 (0.009)
H7 1 2 1 1 1 2 2 1 0.03 (0.005) 0.04 (0.004) 0.012 (0.01)
H8 2 2 2 1 2 2 1 2 0.035 (0.005) 0.032 (0.007) 0.035 (0.009)
H9 2 2 2 2 2 1 1 1 0.031 (0.005) 0.036 (0.004) 0.017 (0.012)
H10 2 2 1 1 1 1 1 2 0.036 (0.006) 0.027 (0.005) 0.03 (0.012)
H11 2 2 2 1 2 2 2 1 0.026 (0.005) 0.029 (0.004) 0.029 (0.011)
H12 1 2 1 1 1 1 1 2 0.017 (0.004) 0.032 (0.005) 0.03 (0.012)
H13 1 2 2 1 2 2 1 1 0.026 (0.006) 0.018 (0.003) 0.03 (0.013)
H14 1 2 1 2 2 2 1 2 0.029 (0.004) 0.014 (0.003) 0.058 (0.01)
H15 2 2 2 2 2 2 2 2 0.025 (0.005) 0.02 (0.005) 0.029 (0.015)
H16 1 2 2 2 2 2 2 1 0.02 (0.006) 0.014 (0.004) 0.03 (0.014)
H17 2 2 2 2 2 1 1 2 0.021 (0.005) 0.019 (0.004) 0.015 (0.01)
H18 1 2 1 1 1 2 2 2 0.018 (0.005) 0.017 (0.003) 0.01 (0.009)
H19 2 2 2 2 2 2 1 1 0.017 (0.004) 0.018 (0.003) 0.005 (0.006)
H20 2 1 1 1 1 1 1 2 0.006 (0.003) 0.025 (0.006) 0.026 (0.013)
H21 1 1 2 2 2 1 1 1 0.015 (0.004) 0.01 (0.002) 0.006 (0.007)
H22 1 2 2 2 2 2 1 2 0.017 (0.004) 0.006 (0.002) 0.005 (0.007)
H23 2 2 2 2 2 2 1 2 0.019 (0.004) 0.007 (0.003) 0.015 (0.01)
aThe estimated haplotype frequencies and standard errors (Std Error) were calculated separately for each of the MHS, Population Control and 50 cDNA CACNA1S sequenced samples using the program PHASE.BMC Medical Genetics 2009, 10:104 http://www.biomedcentral.com/1471-2350/10/104
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This study focused on CACNA1S encoding the 1 subunit
of the DHPR. In the largest study to date, of 50 MH
patients, we identified a single, potentially pathogenic,
variant p.Arg174Trp. The p.Arg174Trp change is situated
at a site that is conserved in rabbit, cat, mouse, and
zebrafish and causes a change in the charge of the amino
acid from basic to non-polar. The amino acid in question
lies in the S4 segment domain of the DHPR thought to
function as a voltage sensor, thus a change in charge may
alter the voltage sensor mechanism and consequently dis-
rupt the cellular calcium homoeostasis. Further functional
work to support these observations would be valuable.
This work also identified two other variants
(p.Gly258Asp, p.Ser606Asn) thought to be polymorphic
as they do not show disease concordancy, but which were
not present in control chromosomes. Whilst it is likely
that they are indeed polymorphisms, the fact that they lie
in conserved regions of the protein and cause a change in
the polarity of the amino acid substituted suggests other-
wise and there is the potential that they could play a
minor role in, or have a modifier effect on, disease pheno-
type. Since there is evidence that MH may not necessarily
be a simple single gene disorder, there is the possibility
that both of these changes are present together with an
additional major change and in some instances account
Dendrogram of the 23 marker haplotypes with estimated population frequency 0.01 (1%), to demonstrate similarities  between haplotypes in terms of disease risk and marker sharing created from the output of a single run of the MCMC algo- rithm in GENEBPM Figure 1
Dendrogram of the 23 marker haplotypes with estimated population frequency 0.01 (1%), to demonstrate 
similarities between haplotypes in terms of disease risk and marker sharing created from the output of a single 
run of the MCMC algorithm in GENEBPM. Haplotypes are coded according to their relative frequency, thus haplotype 1 
is the most common haplotype, and haplotype 23 the least.BMC Medical Genetics 2009, 10:104 http://www.biomedcentral.com/1471-2350/10/104
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for discordancy with disease; i.e. these mutations may be
necessary, but not sufficient, to cause MH susceptibility in
particular individuals.
Comparison of CACNA1S haplotype frequencies between
susceptible cases and UK Caucasian population controls
identified no significant haplotype frequency differences.
Even given that this is the largest standardised and geno-
typed MH database worldwide, there are a limited
number of MH patients, which could reduce the power to
detect a significant association between CACNA1S haplo-
type with MH. However, the haplotype analysis does pro-
vide some evidence for an elevated haplotype diversity,
potentially resulting from the high rate of recombination
observed across the locus and a low level of linkage dise-
quilibrium detected, as seen in the present study and con-
sistent with that observed in the HapMap project.
Coupling this observation with the now growing number
of reported non-pathogenic non-synonymous changes
described across CACNA1S, it is possible that this locus
can tolerate a high degree of variability. This variability
could affect the conformation of the DHPR protein,
which has implications not only in the E-C coupling of
skeletal muscle but also in that of cardiac muscle.
Our data suggest that, whilst CACNA1S may play a role in
MH manifestation in the UK, it is not a major locus,
thereby suggesting that there are other loci with impor-
tance in MH susceptibility. As well as the reported linkage
to chromosome 1q and 19q there are alternative loci pro-
posed on chromosomes 7q [23] and 17q [24], however
no contributory mutations have been identified in these
regions. It is highly probable that any novel genes for MH
susceptibility will play a minor role. An alternative
method to identify genes responsible for MH could be to
take a candidate gene approach and focus on genes whose
products are directly involved with E-C coupling and Ca2+
regulation, for example the other subunits of the DHPR,
calmodulin [25]and JP-45 [26].
Conclusion
We have previously proposed that several independent
genes can influence the MH phenotype [10,22]. Here we
have presented evidence for a novel variant in CACNA1S
which could have the potential to directly influence MH
susceptibility. There was also a possible indirect or modi-
fier effect of CACNA1S in a small number of families,
likely to cause MH in combination with another, as yet
unknown, locus. The evidence for the existence of multi-
ple independent loci that influence MH susceptibility is
now increasing and the disorder appears to be more com-
plex than previously thought. To fully comprehend MH
and all the gene product interactions we need to identify
and characterise all the multiple loci involved.
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